USPTO serial 79320193
XCUBE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 7, 2026
- Examiner
- IN, SUNG HYUN
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with XCUBE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Anna Kurian Shaw
Anna Kurian Shaw Hogan Lovells US LLP555 13th Street NWWashington, DC 20004United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Recorded bioinformatics software for data processing, data engineering, data science, predictive modeling and statistical modeling and machine learning in the field of immunotherapies; recorded graphical user interface software for data processing, data engineering, data science, predictive modeling and statistical modeling and machine learning in the field of immunotherapies; recorded artificial intelligence and machine learning software for genome analysis, developing personal treatment strategies for patients with diagnosed cancer, analyzing, screening, identifying, quantifying, and interpreting data in the field of mass spectrometry and next-generation sequencing (NGS); electronic databases for bioinformatic purposes; next-generation sequencing (NGS) data processor; bioinformatics data processor; none of the foregoing in connection with HVAC systems or components thereof | ACTIVE | — |
| 035 | Compilation of statistical data and models with respect to cancer treatment and cancer diagnosis | ACTIVE | — |
| 042 | Computer programming in the medical, pharmaceutical and biotechnological field; database design in the medical, pharmaceutical and biotechnological field; maintenance of database software in the medical, pharmaceutical, and biotechnological field; programming of software for importing and managing data in the medical, pharmaceutical, and biotechnological field; information technology [IT] consulting services for the pharmaceutical and healthcare industries relating to data processing, data engineering, data science, predictive modeling and statistical modeling and machine learning in the field of immunotherapies; computer programming for data processing; conducting evaluations in the field of pharmaceuticals; consulting services in the fields of biotechnology and pharmaceutical research; pharmaceutical product development and evaluation services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of pharmaceuticals for the treatment of cancer; technical research in the field of pharmaceutical studies; development of platform technology, namely, cancer immunotherapy platforms for manufacturing therapeutics; conducting clinical trials in the field of pharmaceuticals for the treatment and prevention of cancer; providing scientific molecular and genomic information for medical and clinical research, for the treatment of cancer and other diseases and disorders and for individuals' responses to drug treatments; research and development of medicines and diagnostic agents for cancer treatment and cancer diagnosis; providing scientific advice in the fields of cancer biology, cancer treatment, pharmaceutical side effects, genomics, cancer medicine and translational medicine; providing scientific analysis in the field of next-generation sequencing (NGS) with respect to the analysis and interpretation of genomic data obtained from cancer patients; providing an online, non-downloadable computer software platform for purposes of storing and providing information about an individual's cancer profile and genomic changes to enable physicians and healthcare professionals to optimize treatment in clinical practice; research and development services in the field of immunology; none of the foregoing in connection with HVAC systems or components thereof | ACTIVE | — |
| 044 | Medical and pharmaceutical consultancy services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Immatics Biotechnologies GmbH
- Other trademarks owned by Immatics Biotechnologies GmbH
- Other trademarks owned by Immatics Biotechnologies GmbH
- Other trademarks in Class 009
- Other trademarks in Class 035
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named XCUBE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 11, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 11, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Aug 27, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 6, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jul 7, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 7, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Apr 7, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 17, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 17, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 11, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 23, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 6, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 6, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 6, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 8, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 8, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 8, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 16, 2025 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Nov 15, 2024 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Nov 15, 2024 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Nov 15, 2024 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Apr 20, 2024 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Mar 29, 2024 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Mar 29, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 25, 2024 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Sep 25, 2023 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Mar 14, 2023 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Feb 27, 2023 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Feb 22, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 22, 2023 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jan 30, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 30, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 30, 2023 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Nov 28, 2022 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Nov 2, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Nov 2, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 2, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 2, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 2, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 7, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| May 13, 2022 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| May 13, 2022 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| May 13, 2022 | CNSL | SUSPENSION LETTER WRITTEN | — |
| May 12, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 12, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 10, 2022 | ALIE | ASSIGNED TO LIE | — |
| May 6, 2022 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Nov 29, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| Nov 8, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Nov 8, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 14, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 13, 2021 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Oct 7, 2021 | RFWR | NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW | — |
| Sep 24, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 22, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 21, 2021 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Sep 21, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 20, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 16, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |